EAST-ASIA PHARMACEUTICAL released its performance for the first three quarters, with a net loss attributable to the parent company of 72.41 million yuanZhitong·Oct 30, 2025 at 09:22 AM605177+3.64%
The Shanghai Stock Exchange issued regulatory warnings to EAST-ASIA PHARMACEUTICAL and relevant responsible personsWallstreetcn·Oct 22, 2025 at 05:56 AM605177+3.64%
Overview of A-share Stock Buybacks: Today, 4 Companies Disclosed Buyback ProgressZhitong·Aug 24, 2025 at 06:28 PM605177+3.64%601975+0.55%
EAST-ASIA PHARMACEUTICAL: Subsidiary obtains CNAS laboratory accreditation certificateZhitong·Jul 4, 2025 at 03:15 AM605177+3.64%
EAST-ASIA PHARMACEUTICAL: Levofloxacin Tablets Approved for Drug Registration CertificateZhitong·Jun 13, 2025 at 03:44 AM605177+3.64%
EAST-ASIA PHARMACEUTICAL: Quetiapine raw materials have obtained the raw material drug registration certificate in South KoreaZhitong·May 15, 2025 at 02:35 AM605177+3.64%
EAST-ASIA PHARMACEUTICAL released its first-quarter performance, reporting a net loss attributable to the parent company of 6.9196 million yuan, turning from profit to lossZhitong·Apr 29, 2025 at 04:08 AM605177+3.64%
EAST-ASIA PHARMACEUTICAL: The raw material drug Cefotiam has obtained the raw material drug registration certificate in South KoreaZhitong·Apr 1, 2025 at 02:37 AM605177+3.64%
EAST-ASIA PHARMACEUTICAL invests 60 million yuan to establish a wholly-owned subsidiary Zhejiang Shan HengZhitong·Mar 10, 2025 at 02:58 AM605177+3.64%
EAST-ASIA PHARMACEUTICAL: Lu Li Kang Zuo raw materials have obtained the raw material drug registration certificate in South KoreaZhitong·Jan 20, 2025 at 01:36 AM605177+3.64%
EAST-ASIA PHARMACEUTICAL issues a profit warning, expecting a net loss of 95 million to 115 million yuan for the fiscal year 2024Zhitong·Jan 16, 2025 at 01:57 AM605177+3.64%
